Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces β-secretase (BACE1) levels and Aβ generation.
Biochemical inhibition of the acetyltransferases ATase1 and ATase2 reduces β-secretase (BACE1) levels and Aβ generation.
复制标题
DOI:
10.1074/jbc.m111.310136
复制
发表时间:
2012-03-09
期刊:
影响因子:
--
通讯作者:
Puglielli L
中科院分区:
文献类型:
--
作者:
Ding Y;Ko MH;Pehar M;Kotch F;Peters NR;Luo Y;Salamat SM;Puglielli L
Background: The acetyltransferases ATase1 and ATase2 regulate the levels of BACE1, which is involved in the pathogenesis of Alzheimer disease (AD). Results: Both ATases are up-regulated in the brain of AD patients. ATase1/ATase2 inhibitors were identified. Structure-activity relationship, mechanisms of action, and biological effects were determined. Conclusion: ATase1/ATase2 inhibitors down-regulate levels and activity of BACE1. Significance: ATase1/ATase2 are potential targets to prevent AD. The cellular levels of β-site APP cleaving enzyme 1 (BACE1), the rate-limiting enzyme for the generation of the Alzheimer disease (AD) amyloid β-peptide (Aβ), are tightly regulated by two ER-based acetyl-CoA:lysine acetyltransferases, ATase1 and ATase2. Here we report that both acetyltransferases are expressed in neurons and glial cells, and are up-regulated in the brain of AD patients. We also report the identification of first and second generation compounds that inhibit ATase1/ATase2 and down-regulate the expression levels as well as activity of BACE1. The mechanism of action involves competitive and non-competitive inhibition as well as generation of unstable intermediates of the ATases that undergo degradation.